



Bio-Neuroscience™

14 - 15 FEB. 2024 - AMSTERDAM

PROGRAM

THE GLOBAL SUMMIT
FOR LEADERS AND
DECISION-MAKERS IN
CNS NEUROSCIENCES
DRUG DEVELOPMENT

KEY OPINION LEADERS
STARTUPS FOUNDERS
C-LEVEL EXECUTIVES
INDUSTRY EXECUTIVES
INVESTORS

INSIGHT - ACCESS - ENGAGEMENT - IMPACT

AN INITIATIVE OF



BROADREACH
GLOBAL

HOSTED BY



Amsterdam
Neuroscience



DAY I - 14 FEBRUARY

08:15 REGISTRATION OPENS –

08:30 WELCOME COFFEE & NETWORKING

09:00 Initial Welcome Remarks

- Christian J. Suojanen, Founder & CEO - Broadreach Global
- Pieter Van Bokhoven, Chief Scientific Officer, IXA - Amsterdam Neuroscience - UMC

09:15 CNS Neurosciences and Psychiatry – the need for a new generation of novel therapeutics and the policy and ecosystem requirements to accelerate development.

Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- Pawel Świeboda, Founder, NeuroCentury
- Frédéric Destrebecq, Executive Director – European Brain Council (EBC), Brussels
- Martien Kas, President, European College of NeuroPsychopharmacology (ECNP)

09:45 From outward symptoms to underlying biology – where the science is going in neurodegenerative and psychiatric diseases.

Moderator: Juan Carlos Lopez, Managing Director Research Grants – RTW Charitable Foundation

- Stacie Weninger, Executive Director, F-Prime Biomedical Research Initiative
- Joachim Scholpp, Global Head Translational Medicine, CNS & Emerging Areas, Boehringer Ingelheim
- Pieter Van Bokhoven, Chief Scientific Officer, IXA - Amsterdam Neuroscience - UMC
- Jim Sullivan, Chief Executive Officer - Vanqua Biosciences

10:30 COFFEE & NETWORKING BREAK

11:15 Panel Discussion – Panel discussion on enhancing patient selection and clinical trials design for rational drug development in Neurodegeneration.

Moderator: Kalpana Merchant, CSO – Retromer Therapeutics, Adjunct Professor of Neurology – northwestern University Feinberg School of Medicine

- Martien Kas, President, European College of NeuroPsychopharmacology (ECNP)
- Philip Scheltens, EQT Dementia Fund
- John Kastelein, CSO – New Amsterdam Pharma
- Rowan Gardener, Co-Founder & Chief Business & Investment Officer - PrecisionLife



12:00 Discussion Panel – The move to increasing precision medicine approaches in psychiatry.

Moderator: Andrea Soto Padilla, Business Development – Amsterdam Neuroscience

- Joachim Scholpp, Global Head Translational Medicine, CNS & Emerging Areas, Boehringer Ingelheim
- Kees Been, CEO – Kynexis Therapeutics
- Hilgo Bruining, Professor, Neurobiological developmental disorders -Amsterdam UMC. Head - N=You Neurodevelopmental Precision Center.
- Aaron Koenig, Chief Medical Officer – Delix Therapeutics

12:45 LUNCH & NETWORKING BREAK - Sponsored by Warman O'Brien

13:45 Investor Session - The early-stage CNS neuroscience investor perspective.

Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- Raúl Martín-Ruiz, Partner - Ysios Capital.
- David Reynolds, Venture Partner – Dementia Discovery Fund
- Sourav Kole, Managing Director – Dolby Family Ventures
- Stacie Weninger, Executive Director, F-Prime Biomedical Research Initiative
- Hakan Goker, Managing Director – M-Ventures

14:30 COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.

Pitches are 3 minutes, followed by 3 minutes Q&A led by the jury.

Moderator: Amanda Borgerhoff, VP Client Services, Warman O'Brien

- Karla Therapeutics - Simon Loiodice, CEO
- ToxGen Solutions – Stan Goertz, Business Development
- Evecxia - Jacob Jacobsen, CEO
- Healix Therapeutics - Sebastian de Beurs, Co-Founder & COO
- Pangea Bio – Lars Christian Wilde, CEO, Chairman & Co-Founder
- Neurocentrx - Jeff Roix, CEO
- Kernel - Ryan Field, CEO

Meet the presenters following the pitch session at their tables in the networking area.

15:15 COFFEE & NETWORKING BREAK



15:45 Gene therapy, RNA and advanced therapies in Neurodegenerative Disease.

Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- José Luis Lanciego, Chair – International Brain Research Organization Pan European Committee, Head – Laboratory of Functional Neuroanatomy of the Basal Ganglia, CNS Gene Therapy Program – CIMA, University of Navarra
- Kalpana Merchant, CSO – Retromer Therapeutics
- Jason Dictenberg, CEO, SpliceRNA
- Dee Datta, CEO, Switch Therapeutics
- Maria Luisa Pineda, Co-Founder & CEO – Envisagenics

16:45 COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.

Pitches are 3 minutes, followed by 3 minutes Q&A led by the jury.

Moderator: Lieza Exalto, Scientific Officer, Julius Clinical

- NRG Therapeutics - Neil Miller, CEO
- GAIN Therapeutics - Joanne Taylor, CEO
- a:head Bio - Josh Bagley, Chief Scientific Officer
- NeuroSoV - Dina Pereira, CEO & Co-Founder
- PharmaKure - Farid Khan, CEO
- Stalicia - Lynn Durham, CEO & Co-Founder
- Neurodex - Oded Biran, CEO
- Golgi Neurosciences - Chiara Rossana Maria, Managing Director

Meet the presenters following the pitch session at their tables in the networking area.

17:35 END OF DAY I PROGRAM & NETWORKING RECEPTION



DAY II - 15 FEBRUARY

08:15 REGISTRATION OPENS –

08:30 COFFEE & NETWORKING

09:00 Opening Remarks

09:15 Advanced therapeutics for rare neurological diseases – the potential, challenges, and strategies for success.

Moderator: Juan Carlos Lopez, Managing Director, Research Grants – RTW Charitable Foundation

- Yael Weiss, CEO - Mahzi
- Terry Pirovolakis, Founder & CEO – Elpida Therapeutics
- Ruud Toonen, Professor - VU University Amsterdam

10:00 Growth company panel: Advancing the pipeline and navigating current market conditions.

Moderator: Cillian King, Managing Director – EQT Life Sciences

- Mary Chamberlain-Tharp, Chief Business Officer – Neumora
- Carlos Buesa, Founder & Chairman of the Board - Oryzon
- Craig Thompson, CEO, Cerevance
- Niels Plath, Chief Scientific Officer - Muna Therapeutics

10:45 COFFEE & NETWORKING BREAK - Sponsored by Julius Clinical

11:15 Industry Panel – Partnering with Industry on CNS neuroscience drug development

Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- Florian Brand, CEO & Co-Founder, atai Life Sciences
- Christian Thomsen, Global Head CNS Business Development & Licensing, Boehringer Ingelheim, Germany
- Olga Krylova, Director of Business Development & Innovation, Otsuka Pharmaceutical Companies Europe
- Jeremy Quirk, Vice President BD&L Commercial Portfolio - GSK



12:15 COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.

Pitches are 3 minutes, followed by 3 minutes Q&A led by the jury.

Moderator: Graham Combe: Founder, BioSell

- Synendos Therapeutics AG - Andrea Chicca, CEO & CSO
- Mireca Medicines - Barbara Brunnhuber, CEO
- Kasvu Therapeutics - Jami Mandelin, CEO
- 2N Pharma - Preben Bruun-Nyzell, CEO
- NEGEV Labs - Heresh Rezavandi, Chief Strategy & Partnering Officer
- Draig Therapeutics - Richard Angell, Chief Commercialization Lead
- Pathios Therapeutics - Stuart Hughes, CEO

Meet the presenters following the pitch session at their tables in the networking area.

13:00 NETWORKING LUNCH – Exhibition area

14:00 Investor Session – biopharma VCs, CNS neuroscience is back.

Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- Arno de Wilde, Director – EQT Life Sciences
- Jasper Bos, General Partner - Forbion
- Kostia Adamsky, COO & Co-Founder - NEGEV Capital
- Delphine Charvin, Operating Partner, ARGOBIO Studio
- Claire Leurent, Managing Director – Abbvie Ventures

15:00 Wrap up Discussion

Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- Mark Treherne, Chairperson – Monument Therapeutics
- David Reynolds, Venture Partner – Dementia Discovery Fund, SV Health Investors
- Sourav Kole, Managing Director – Dolby Family Ventures

15:45 Bio-Neuroscience Pitch Award – As selected by the investor and industry jury.

16:00 WRAP & CLOSING REMARKS – NETWORKING

STRATEGIC PARTNERS

